Eagle Asset Management Inc. purchased a new stake in Horizon Pharma Inc. (NASDAQ:HZNP) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,463,170 shares of the biopharmaceutical company’s stock, valued at approximately $26,527,000. Eagle Asset Management Inc. owned about 0.91% of Horizon Pharma at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. First Dallas Securities Inc. raised its stake in Horizon Pharma by 9.6% in the second quarter. First Dallas Securities Inc. now owns 32,430 shares of the biopharmaceutical company’s stock valued at $534,000 after buying an additional 2,850 shares in the last quarter. BlackRock Group LTD raised its stake in Horizon Pharma by 2.9% in the second quarter. BlackRock Group LTD now owns 103,891 shares of the biopharmaceutical company’s stock valued at $1,712,000 after buying an additional 2,972 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Horizon Pharma by 11.1% in the second quarter. Teacher Retirement System of Texas now owns 33,613 shares of the biopharmaceutical company’s stock valued at $554,000 after buying an additional 3,363 shares in the last quarter. CAM Group Holding A S raised its stake in Horizon Pharma by 0.5% in the second quarter. CAM Group Holding A S now owns 665,000 shares of the biopharmaceutical company’s stock valued at $10,953,000 after buying an additional 3,500 shares in the last quarter. Finally, Carl Domino Inc raised its stake in Horizon Pharma by 36.4% in the second quarter. Carl Domino Inc now owns 15,000 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Shares of Horizon Pharma Inc. (NASDAQ:HZNP) traded down 0.97% during mid-day trading on Friday, hitting $21.49. The company’s stock had a trading volume of 630,634 shares. The company’s market cap is $3465.41 billion. The stock has a 50-day moving average of $18.68 and a 200-day moving average of $18.49. Horizon Pharma Inc. has a 12-month low of $13.05 and a 12-month high of $23.44.

Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.07. The business had revenue of $273.70 million for the quarter, compared to analyst estimates of $270.04 million. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. The company’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. On average, equities research analysts forecast that Horizon Pharma Inc. will post $2.02 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Eagle Asset Management Inc. Purchases New Position in Horizon Pharma Inc. (HZNP)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/27/eagle-asset-management-inc-purchases-new-position-in-horizon-pharma-inc-hznp.html.

A number of brokerages have recently issued reports on HZNP. Zacks Investment Research upgraded Horizon Pharma from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, August 10th. Brean Capital reiterated a “buy” rating and set a $30.00 target price on shares of Horizon Pharma in a research report on Tuesday, August 9th. Guggenheim reiterated a “buy” rating and set a $30.00 target price on shares of Horizon Pharma in a research report on Tuesday, August 23rd. Mizuho reiterated a “buy” rating and set a $30.00 target price (up previously from $24.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price (up previously from $29.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Horizon Pharma presently has a consensus rating of “Buy” and an average price target of $29.69.

About Horizon Pharma

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.